Last updated: 2026-09-04 16:59:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Scienture Holdings, Inc. (SCNX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.37, with a market capitalization of $15.19M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.24 to $2.60. This page covers its latest market performance, valuation, price trends and company information.
$15.19M | |
$0.39 | |
$9.55 | |
$0.24 | |
$0.37 | |
102.06K | |
-- | |
-- | |
$2.60 | |
$0.24 | |
-- | |
-- |
Scienture Holdings, Inc. (SCNX) is currently trading at $0.37 as of 2026-09-04 16:57:00, down 0.49% ($0.00) from the previous close of $0.37
During today's regular trading session, SCNX has traded between $0.24 and $9.55, with a trading volume of 102.06K shares. The current price is near the lower end of today's range.
Over the past seven days, Scienture Holdings, Inc. (SCNX) moved from $0.39 to $0.37, representing a decline of 6.60% ($0.03).
The stock traded between $0.37 and $0.39 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 227.82 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 5.5%
SCNX is currently trading at $0.37, placing it 5.5% of the way from its 52-week low of $0.24 to its 52-week high of $2.60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 9 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Scienture Holdings, Inc. (SCNX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.